Gastroschisis
Methodology & AI Transparency ⓘ
Gastroschisis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Gastroschisis is an ICD-10-CM indexed diagnosis (Q79.3) within Children's & Adolescent Health.
- 2 Real-world patient consensus: Mapped to Children's & Adolescent Health under ICD-10-CM Q79.3 for Gastroschisis clinical workups.
- 3 Typical cash cost range: Differential triage of Gastroschisis (Q79.3) utilizes family-centered specialist care [Gastroschisis Q79.3].
- 4 Top reported side effects / signs: Follow-up benchmark in Gastroschisis: maintaining WHO / CDC in Gastroschisis (Q79.3: Age-Adjusted Growth Percentiles) within Consistent personal growth curve tracking (Q79.3).
Ask our AI Specialists anything about Gastroschisis
What Is Gastroschisis?
Gastroschisis is an ICD-10-CM indexed diagnosis (Q79.3) within Children's & Adolescent Health. Clinical evaluation centers on family-centered specialist care [Gastroschisis Q79.3] alongside serial WHO / CDC in Gastroschisis (Q79.3: Age-Adjusted Growth Percentiles) tracking (Consistent personal growth curve tracking (Q79.3)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Gastroschisis (Q79.3) features or congenital embryologic in Gastroschisis (Q79.3: structural variation). therapeutic stabilization in pediatrics is verified against Pediatric Hemoglobin & in Gastroschisis (Q79.3: Lead Screen).
Common Symptoms & Clinical Signs
- • Presentation of Gastroschisis (Q79.3): pediatric skin rashes, in Gastroschisis (Q79.3: gastrointestinal discomfort, or)
- • Secondary Gastroschisis clinical sign: growth velocity shifts, in Gastroschisis (Q79.3: newborn feeding/jaundice signs,)
- • Symptom flares in Gastroschisis correlating with WHO / CDC in Gastroschisis (Q79.3: Age-Adjusted Growth Percentiles) deviation outside Consistent personal growth curve tracking (Q79.3)
- • Functional pediatrics impact requiring family-centered specialist care [Gastroschisis Q79.3] evaluation (Q79.3)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Gastroschisis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | Q79.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Children's & Adolescent Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: WHO / CDC in Gastroschisis (Q79.3: Age-Adjusted Growth Percentiles) | Consistent personal growth curve tracking (Q79.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pediatric Hemoglobin & in Gastroschisis (Q79.3: Lead Screen) | Age-normal hemoglobin; blood lead < 3.5 mcg/dL (Q79.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Gastroschisis
Treatment selection for Gastroschisis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gastroschisis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of Vitamin B 12 Supplementation on Leukocyte Telomere Length in Mildly Providing daily vitamin B 12 for 1 y during infancy in a population at risk of vitamin B 12 deficiency does not affect LTL. The Journal of nutrition • 2024-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37918674 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-Dose Remifentanil in Preterm Cesarean Section with General The use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes. Paediatric drugs • 2024-01-15 • Phase III Randomized Trial | N = 27 | 88/100 | PMID 37713021 ↗ |
| Can This Approach Help? Inside the Latest Research on Mass Administration of Azithromycin to Infants in Mali to Reduce Mass administration of azithromycin in Mali, limited to infants 1 to 11 months of age, did not result in lower infant or child mortality than placebo, regardless of whether azithromycin was delivered twice yearly or quarterly. The New England journal of medicine • 2025-10-16 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41092331 ↗ |
Gastroschisis Patient Community & “People Like Me” Threads
Filter Gastroschisis community threads and patient logs by age, biological sex, dosage, and treatment duration.